Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals’ portfolio of Factor XIa inhibitors to expand its offerings in the anticoagulation market.
Under the deal, eXIthera will receive up to $15m in milestone payments from Cadrenal, contingent on clinical and regulatory achievements and is eligible for royalties from global sales of the assets acquired.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition includes eXIthera’s lead candidate, frunexian, a Phase II-ready intravenous (IV) Factor XIa inhibitor intended for acute care applications.
It also includes the oral inhibitor, EP-7327, targeting long-term thrombotic conditions, along with a portfolio of additional novel FXIa small molecules.
Cadrenal obtains global rights to the assets, except in China, where Sichuan Haisco Pharmaceuticals retains them under a previous agreement with eXIthera.
Cadrenal Therapeutics chairman and CEO Quang Pham said: “With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“These newly acquired assets will expand Cadrenal’s capabilities in an effort to address even more critical gaps in current antithrombotic treatment, especially for patients for whom current therapies are unreliable or carry excessive bleeding risk.”
Cadrenal said, unlike existing anticoagulants that affect coagulation, eXIthera’s Factor Xia inhibitors offer controlled and selective therapeutic effects.
The company’s lead product, tecarfarin, is an investigational oral anticoagulant that addresses challenges in managing vitamin K antagonists.
Tecarfarin aims to mitigate the risks associated with commonly used anticoagulants such as warfarin, which have notable side effects.
Pham added: “This acquisition reinforces Cadrenal’s long-term vision of becoming a category leader in anticoagulation.
“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD [left ventricular assist device] patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk.”
